New Course on Pharmaceutical Development: From Drug Lead to Drug Product

*********************************
There is now a CONTENT FREEZE for Mercury while we switch to a new platform. It began on Friday, March 10 at 6pm and will end on Wednesday, March 15 at noon. No new content can be created during this time, but all material in the system as of the beginning of the freeze will be migrated to the new platform, including users and groups. Functionally the new site is identical to the old one. webteam@gatech.edu
*********************************

Event Details
  • Date/Time:
    • Tuesday May 29, 2012 - Tuesday June 12, 2012
      1:00 pm - 8:59 pm
  • Location: Georgia Tech
  • Phone:
  • URL:
  • Email:
  • Fee(s):
    N/A
  • Extras:
Contact

Mark Prausnitz, PhD - Regents' Professor of Chemical and Biomedical Engineering, Love Family Professor of Chemical & Biomolecular Engineering  Donna Bondy - Administrative Coordinator Phone: +1 (404) 385-2944 Email: bondy@gatech.edu

Summaries

Summary Sentence: A new, interdisciplinary short‐course for doctoral students engaged in pharmaceutical research at Atlanta-area universities.

Full Summary: New Course on Pharmaceutical Development: From Drug Lead to Drug Product

A new, interdisciplinary short‐course for doctoral students engaged in pharmaceutical research at Georgia Tech, Mercer, Emory, Georgia State and other Atlanta‐area universities offered Summer 2012 (May 29 – June 11).

  • Instructor: Mark Prausnitz (head instructor) with co‐instructors and guest lecturers from Atlanta‐area universities and companies
  • Prerequisites: Graduate standing with intent to pursue a PhD focused on pharmaceutical research. 
  • Course credit: 3 units 
  • Course meeting time: 9 AM – 5 PM on May 29, 30, 31; June 1, 4, 5, 6, 7, 8, 11 
  • Course meeting location: Georgia Tech campus 
  • Course number: CHBE 8803 (at Georgia Tech) or IBS 500R/course number 2073 (at Emory) (Students from other universities should cross register at Georgia Tech; see requirements

Course description:
Doctoral students from biochemistry, bioengineering, pharmacology, pharmacy, and other fields will work as part of interdisciplinary teams to simulate the drug development process starting with a druggable lead and ending with a report to “upper management” giving the scientific and business plan for development into an approved drug product. The course will follow an intensive, all‐day, short‐course format for ten consecutive weekdays with faculty lectures and student project teamwork. The goal of the course is to teach students the multifaceted process needed to bring a drug from concept to market in the context of open‐ended, student‐driven, collaborative projects addressing real‐world problems in pharmaceutical development.

Course syllabus:
Class Topics
May 29 - Introduction to class and pharmaceutical development Elements of an IND and NDA Design and discovery of druggable molecules
May 30 - From drug lead to drug molecule Project teamwork and communication
May 31 - Target indication, patient population
June 1 - Drug manufacturing scale up and GMP
June 4 - Formulation, route of administration, drug delivery systems
June 5 - Design of IND‐enabling studies: CMC, PK/PD and toxicology
June 6 - Clinical trial design
June 7 - Pharmaceutical marketing
June 8 - Oral presentations and reports / business plan
June 11 - Final presentations

Partial list of confirmed speakers: Ajay Banga (Mercer), Andy Bommarius (Georgia Tech), Mark Prausnitz (Georgia Tech), Jaipal Singh (Emory/SJTRI), Charlie Thompson (Axtria), Wes Wynens (Georgia Tech) and others.

Additional Information

In Campus Calendar
Yes
Groups

Parker H. Petit Institute for Bioengineering and Bioscience (IBB)

Invited Audience
No audiences were selected.
Categories
No categories were selected.
Keywords
Mark Prausnitz, New Course on Pharmaceutical Development: From Drug Lead to Drug Product
Status
  • Created By: Colly Mitchell
  • Workflow Status: Published
  • Created On: Mar 15, 2012 - 8:11am
  • Last Updated: Oct 7, 2016 - 9:58pm